Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

Results 11-20 of 26 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2011A substance P antagonist improves outcome when administered 4 h after onset of ischaemic strokeTurner, R.; Helps, S.; Thornton, E.; Vink, R.
2012Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's DiseaseThornton, E.; Vink, R.
2012Substance P-induced changes in cell genesis following diffuse traumatic brain injuryCarthew, H.; Ziebell, J.; Vink, R.
2013Substance P as a mediator of neurogenic inflammation after balloon compression induced spinal cord injuryLeonard, A.; Thornton, E.; Vink, R.
2014Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumorsHarford-Wright, E.; Lewis, K.; Ghabriel, M.; Vink, R.
2014Changes in substance P and NK1 receptor immunohistochemistry following human spinal cord injuryLeonard, A.; Manavis, J.; Blumbergs, P.; Vink, R.
2012Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumoursLewis, K.; Harford-Wright, E.; Vink, R.; Ghabriel, M.
2014Advancing drug therapy for brain tumours: a current review of the pro-inflammatory peptide substance P and its antagonists as anti-cancer agentsMander, K.; Harford-Wright, E.; Lewis, K.; Vink, R.
2013The role of substance P in ischaemic brain injuryTurner, R.; Vink, R.
2013The potential for substance P antagonists as anti-cancer agents in brain tumoursHarford-Wright, E.; Lewis, K.; Vink, R.